Milton Packer In the REVIVE trial the inotropic agent levosimendan has improved short-term outcome in acutely decompensated heart failure. Milton Packer from the University of Texas. [audio:https://ww
Milton Packer
In the REVIVE trial the inotropic agent levosimendan has improved short-term outcome in acutely decompensated heart failure.Milton Packerfrom the University of Texas.
Related Episodes
COMMENTS
Gordon Tomaselli Gordon Tomaselli commented on Milton Packer’s findings at the Dallas meeting of the American Heart Association. [audio:https://www.audiomedica.com/podcasting/aha2005/Gordon_Toma
16 November 2005
0:00